LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Novel grading system for CADASIL severity: A multicenter cross-sectional study.

    Anisetti, Bhrugun / Greco, Elena / Stojadinovic, Eldina / Goldstein, Eric D / Sakusic, Amra / Badi, Mohammed K / Liu, Michael D / Lin, Michelle P / Chiang, Chia-Chun / Elahi, Fanny M / Worrall, Bradford B / Petrosian, Derek / Ross, Owen / Meschia, James F

    Cerebral circulation - cognition and behavior

    2023  Volume 5, Page(s) 100170

    Abstract: Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited progressive cerebral microangiopathy with considerable phenotypic variability. The purpose of this study was to describe the ...

    Abstract Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited progressive cerebral microangiopathy with considerable phenotypic variability. The purpose of this study was to describe the generalizability of a recently proposed grading system of CADASIL across multiple centers in the United States.
    Methods: Electronic medical records (EMR) of an initial neurological assessment of adult patients with confirmed CADASIL were reviewed across 5 tertiary referral medical centers with expertise in CADASIL. Demographic, vascular risk factors, and neuroimaging data were abstracted from EMR. Patients were categorized into groups according to the proposed CADASIL grading system: Grade 0 (asymptomatic), Grade 1 (migraine only), Grade 2 (stroke, TIA, or MCI), Grade 3 (gait assistance or dementia), and Grade 4 (bedbound or end-stage). Inter-rater reliability (IRR) of grading was tested in a subset of cases.
    Results: We identified 138 patients with a mean age of 50.9 ± 13.1 years, and 57.2% were female. The IRR was acceptable over 33 cases (κ=0.855, SD 0.078,
    Conclusion: The CADASIL severity grading system is a pragmatic, reliable system for characterizing CADASIL phenotype that does not require testing beyond that done in standard clinical practice. Higher severity grades tended to have a higher vascular risk factor burden. This system offers a simple method of categorizing CADASIL patients which may help to describe populations in observational and interventional studies.
    Language English
    Publishing date 2023-06-11
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2666-2450
    ISSN (online) 2666-2450
    DOI 10.1016/j.cccb.2023.100170
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma.

    Liu, Michael D / Uaje, Michelle B / Al-Ghazi, Muthana S / Fields, Denise / Herman, June / Kuo, Jeffrey V / Milne, Norah / Nguyen, Thong H / Ramsinghani, Nilam S / Tokita, Kenneth M / Tsai, Fong Y / Vajgrt, Duane J / Imagawa, David K

    The American surgeon

    2004  Volume 70, Issue 11, Page(s) 947–953

    Abstract: This is a retrospective analysis of a new treatment modality, intra-arterial administration of Yttrium-90 TheraSphere, for unresectable hepatocellular carcinoma (HCC). Patients with HCC not amenable to surgical treatment who had satisfactory ... ...

    Abstract This is a retrospective analysis of a new treatment modality, intra-arterial administration of Yttrium-90 TheraSphere, for unresectable hepatocellular carcinoma (HCC). Patients with HCC not amenable to surgical treatment who had satisfactory physiological function without comorbid disease or significant pulmonary shunting were eligible for treatment. Patients were categorized into complete, partial, or no response based on serum alpha-fetoprotein (AFP) levels and CT or MRI imaging. Fourteen patients were considered candidates for treatment. Three patients were excluded due to significant hepatopulmonary shunting. Eleven patients were treated with TheraSphere. One patient (9%) had a complete response, eight patients (78%) had a partial response, and two patients (18%) showed no response. Partial and complete responders with AFP-associated HCC demonstrated a median decrease in AFP levels of 79 per cent at 73 days. No patients developed liver toxicity nor died due to treatment. Five patients (45%) died of progressive disease at a median of 7 months post-treatment. Six patients (54%) were alive at a median of 11 months (range, 9 to 20 months). Okuda stage 2 and 3 patients showed a median survival of 11 months and 7 months, respectively. Yttrium-90 TheraSphere treatment for unresectable hepatocellular carcinoma is well tolerated and appears to extend survival.
    MeSH term(s) Aged ; Brachytherapy/methods ; Carcinoma, Hepatocellular/radiotherapy ; Carcinoma, Hepatocellular/therapy ; Catheterization ; Female ; Hepatic Artery ; Humans ; Liver Neoplasms/radiotherapy ; Liver Neoplasms/therapy ; Male ; Microspheres ; Middle Aged ; Radiotherapy Dosage ; Retrospective Studies ; Treatment Outcome ; Yttrium Radioisotopes/administration & dosage ; Yttrium Radioisotopes/therapeutic use
    Chemical Substances Yttrium Radioisotopes
    Language English
    Publishing date 2004-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 202465-2
    ISSN 1555-9823 ; 0003-1348
    ISSN (online) 1555-9823
    ISSN 0003-1348
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top